Literature DB >> 22940268

Brain regional differences in CB1 receptor adaptation and regulation of transcription.

M F Lazenka1, D E Selley, L J Sim-Selley.   

Abstract

Cannabinoid CB1 receptors (CB1Rs) are expressed throughout the brain and mediate the central effects of cannabinoids, including Δ(9)-tetrahydrocannabinol (THC), the main psychoactive constituent of marijuana. Repeated THC administration produces tolerance to cannabinoid-mediated effects, although the magnitude of tolerance varies by effect. Consistent with this observation, CB1R desensitization and downregulation, as well as induction of immediate early genes (IEGs), vary by brain region. Zif268 and c-Fos are induced in the forebrain after acute THC administration. Phosphorylation of the cAMP response-element binding protein (CREB) is increased in a region-specific manner after THC administration. Results differ between acute versus repeated THC injection, and suggest that tolerance to IEG activation might develop in some regions. Repeated THC treatment produces CB1R desensitization and downregulation in the brain, although less adaption occurs in the striatum as compared to regions such as the hippocampus. Repeated THC treatment also induces expression of ΔFosB, a very stable isoform of FosB, in the striatum. Transgenic expression of ∆FosB in the striatum enhances the rewarding effects of several drugs, but its role in THC-mediated effects is not known. The inverse regional relationship between CB1R desensitization and ∆FosB induction suggests that these adaptations might inhibit each other, although this possibility has not been investigated. The differential regional expression of individual IEGs by acute or repeated THC administration suggests that regulation of target genes and effects on CB1R signaling will contribute to the behavioral effects of THC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22940268      PMCID: PMC3772765          DOI: 10.1016/j.lfs.2012.08.023

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  65 in total

1.  Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice.

Authors:  Victoria Mendizábal; Andreas Zimmer; Rafael Maldonado
Journal:  Neuropsychopharmacology       Date:  2005-11-16       Impact factor: 7.853

2.  Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain.

Authors:  J Villares
Journal:  Neuroscience       Date:  2007-01-10       Impact factor: 3.590

Review 3.  Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons.

Authors:  Anders Borgkvist; Gilberto Fisone
Journal:  Neurosci Biobehav Rev       Date:  2006-05-30       Impact factor: 8.989

4.  Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration.

Authors:  Laura J Sim-Selley; Nicole S Schechter; W Kirk Rorrer; George D Dalton; Jerry Hernandez; Billy R Martin; Dana E Selley
Journal:  Mol Pharmacol       Date:  2006-06-07       Impact factor: 4.436

5.  Distinct patterns of DeltaFosB induction in brain by drugs of abuse.

Authors:  L I Perrotti; R R Weaver; B Robison; W Renthal; I Maze; S Yazdani; R G Elmore; D J Knapp; D E Selley; B R Martin; L Sim-Selley; R K Bachtell; D W Self; E J Nestler
Journal:  Synapse       Date:  2008-05       Impact factor: 2.562

Review 6.  The role of CB1 receptors in psychostimulant addiction.

Authors:  Joost Wiskerke; Tommy Pattij; Anton N M Schoffelmeer; Taco J De Vries
Journal:  Addict Biol       Date:  2008-06       Impact factor: 4.280

7.  Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure.

Authors:  William Renthal; Tiffany L Carle; Ian Maze; Herbert E Covington; Hoang-Trang Truong; Imran Alibhai; Arvind Kumar; Rusty L Montgomery; Eric N Olson; Eric J Nestler
Journal:  J Neurosci       Date:  2008-07-16       Impact factor: 6.167

8.  CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.

Authors:  T Rubino; C Guidali; D Vigano; N Realini; M Valenti; P Massi; D Parolaro
Journal:  Neuropharmacology       Date:  2007-07-06       Impact factor: 5.250

9.  Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

Authors:  Deepak Cyril D'Souza; Mohini Ranganathan; Gabriel Braley; Ralitza Gueorguieva; Zoran Zimolo; Thomas Cooper; Edward Perry; John Krystal
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

10.  Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade.

Authors:  Tiziana Rubino; Daniela Viganò; Fabrizio Premoli; Chiara Castiglioni; Silvia Bianchessi; Renata Zippel; Daniela Parolaro
Journal:  Mol Neurobiol       Date:  2006-06       Impact factor: 5.682

View more
  15 in total

1.  Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors:  Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-10       Impact factor: 4.147

2.  Pharmacology: Cannabis in neurology--a potted review.

Authors:  Richard Hosking; John Zajicek
Journal:  Nat Rev Neurol       Date:  2014-07-08       Impact factor: 42.937

3.  Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.

Authors:  Monika Feliszek; Laura Bindila; Beat Lutz; Andreas Zimmer; Andras Bilkei-Gorzo; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-03-17       Impact factor: 3.000

4.  Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Authors:  Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2013-02-14       Impact factor: 4.030

5.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

6.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

Review 7.  Associative and sensorimotor cortico-basal ganglia circuit roles in effects of abused drugs.

Authors:  C M Gremel; D M Lovinger
Journal:  Genes Brain Behav       Date:  2016-08-26       Impact factor: 3.449

8.  Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.

Authors:  Robert B Laprairie; Amina M Bagher; Melanie E M Kelly; Denis J Dupré; Eileen M Denovan-Wright
Journal:  J Biol Chem       Date:  2014-07-18       Impact factor: 5.157

9.  Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.

Authors:  Brian D Kangas; Michael Z Leonard; Vidyanand G Shukla; Shakiru O Alapafuja; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2016-01-29       Impact factor: 4.030

10.  Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation.

Authors:  Tricia H Smith; Lawrence C Blume; Alex Straiker; Jordan O Cox; Bethany G David; Julie R Secor McVoy; Katherine W Sayers; Justin L Poklis; Rehab A Abdullah; Michaela Egertová; Ching-Kang Chen; Ken Mackie; Maurice R Elphick; Allyn C Howlett; Dana E Selley
Journal:  Mol Pharmacol       Date:  2015-02-05       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.